Venous thromboembolism is a very common and costly health problem worldwide.
Anticoagulant treatment for VTE is imperfect: all have the potential for significant bleeding …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

The use of direct oral anticoagulants for stroke prevention in atrial fibrillation continues to
rise. Certain populations may be at higher risk for increased drug exposure and adverse …

Background Emerging safety and efficacy data for rivaroxaban suggest traditional therapy
and rivaroxaban are comparable in the morbidly obese. However, real‐world data that …

1Oxford University Hospitals NHS Trust, Oxford, 2Liverpool Centre for Cardiovascular
Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK …

To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …

Abstract Introduction Direct oral anticoagulants (DOACs) have the potential to increase
bleeding due to drug-drug interactions (DDIs). In the present study, the risk of bleeding was …

Objective To establish the risk of major bleeding in direct oral anticoagulant (DOAC) users
(overall and by class) versus vitamin K antagonist (VKA) users, using health care databases …

Purpose: To systematically review available evidence of indirect comparisons from RCTs
and direct comparisons from observational studies regarding the comparative effectiveness …

Aims The introduction of direct oral anticoagulants (DOACs) has broadened the treatment
arsenal for nonvalvular atrial fibrillation, but observational studies on the benefit–risk …